A New Breed of Generic Drugs Poised to Disrupt

It was a day many big biotechs and pharmas feared but one that consumers should celebrate -- the world's first biosimilar monoclonal antibodies were recommended for approval in Europe. The drug set to face a new cheap generic threat is Remicade, a $6 billion rheumatoid arthritis blockbuster and Johnson & Johnson's biggest seller.

In this video, health-care analyst David Williamson discusses the big picture importance of this EU decision, why J&J investors shouldn't panic, and why the company responsible for the biosimilar may deserve a second look.

Rising health-care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health-care system -- and how to potentially profit from this trend -- click here for free, immediate access.

Follow David on Twitter: @MotleyDavid.

The article A New Breed of Generic Drugs Poised to Disrupt originally appeared on Fool.com.

David Williamson owns shares of Johnson & Johnson and Merck. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends Johnson & Johnson and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.